Latest Revenue Generation News

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Wiseway Group delivered 10.1% revenue growth to $205.6 million in FY26, led by a 22.2% surge in its eCommerce Solutions division, while maintaining EBITDA margins amid cost discipline. The Group declared a fully franked final dividend of 0.6 cents per share.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Alfabs Australia delivered an 11% revenue increase and improved free cash flow in FY26, progressing its debt restructuring and setting the stage for dividend reinstatement.

Butn Limited reported a 5% revenue increase to $15.3 million in FY26, driven by strong platform growth and strategic simplification, while net loss widened 44% to $3.8 million amid higher bad debts and one-off costs.

Pengana Capital Group reported a statutory loss of $5.6 million for FY26 despite a 14% rise in funds under management, driven by upfront costs linked to new product launches and expanding private credit platforms.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Metallium has resolved a key permitting constraint at its Texas Gator Point campus, enabling chlorinated Flash Joule Heating testing to resume ahead of a major September campaign. The company also marks first revenue from its MXene development program and strengthens engineering leadership.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

SportsHero Limited has partnered with Carry1st to distribute gaming top-up vouchers and ePINs via its HeroPlay platform, adding major titles and platform vouchers to its Southeast Asian offering.

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.